The current standard for stage IIIB cervical cancer is primary external beam radiation + concurrent cisplatin based chemotherapy + brachytherapy (see NCCN guidelines CERV6). Clearly, given the failure rate with distant metastases after primary therapy, there exists significant interest in adjuvant c...

We know these patients are at high risk of recurrence due to their advanced stage disease, though we do not have clear data to show the benefit of additional chemotherapy after chemoradiation. Dueñas-González et al published a study to assess whether the addition of gemcitabine to...

There is limited level I evidence to support this. So technically the "standard" is to observe after upfront chemoradiation, but we have done this in women who seem to have possibly persistent disease... Not sure if this answers the question?